Cambridge Investment Research Advisors Inc. increased its position in shares of Humana Inc. (NYSE:HUM – Free Report) by 28.7% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,072 shares of the insurance provider’s stock after buying an additional 1,577 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in Humana were worth $3,162,000 as of its most recent SEC filing.
A number of other hedge funds have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its stake in Humana by 0.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 7,667,648 shares of the insurance provider’s stock worth $3,722,338,000 after buying an additional 44,518 shares during the last quarter. FMR LLC lifted its position in Humana by 7.1% during the 1st quarter. FMR LLC now owns 7,342,938 shares of the insurance provider’s stock worth $3,564,703,000 after acquiring an additional 486,893 shares during the period. State Street Corp lifted its position in Humana by 0.5% during the 1st quarter. State Street Corp now owns 5,708,167 shares of the insurance provider’s stock worth $2,776,072,000 after acquiring an additional 25,832 shares during the period. GQG Partners LLC lifted its position in Humana by 4.5% during the 1st quarter. GQG Partners LLC now owns 2,243,042 shares of the insurance provider’s stock worth $1,088,907,000 after acquiring an additional 96,896 shares during the period. Finally, Geode Capital Management LLC lifted its position in Humana by 0.8% during the 1st quarter. Geode Capital Management LLC now owns 2,234,477 shares of the insurance provider’s stock worth $1,082,060,000 after acquiring an additional 16,692 shares during the period. Hedge funds and other institutional investors own 91.86% of the company’s stock.
Wall Street Analyst Weigh In
A number of analysts have weighed in on HUM shares. Stephens increased their price objective on Humana from $555.00 to $560.00 and gave the stock an “overweight” rating in a research report on Thursday, August 3rd. Royal Bank of Canada decreased their price objective on Humana from $637.00 to $594.00 and set an “outperform” rating for the company in a research report on Thursday, August 3rd. Sanford C. Bernstein raised their price target on Humana from $568.00 to $599.00 and gave the company a “market perform” rating in a report on Tuesday, August 8th. Morgan Stanley reduced their price objective on Humana from $637.00 to $624.00 and set an “overweight” rating for the company in a report on Wednesday, August 30th. Finally, TD Cowen dropped their price target on Humana from $616.00 to $613.00 and set an “outperform” rating for the company in a research report on Tuesday, August 15th. Four research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, Humana presently has a consensus rating of “Moderate Buy” and a consensus target price of $594.53.
Humana Trading Up 0.1 %
Shares of NYSE HUM opened at $493.57 on Thursday. The stock’s 50 day moving average price is $475.96 and its two-hundred day moving average price is $486.52. Humana Inc. has a 52-week low of $423.29 and a 52-week high of $571.30. The stock has a market capitalization of $61.16 billion, a P/E ratio of 18.42, a PEG ratio of 1.29 and a beta of 0.66. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.58.
Humana (NYSE:HUM – Get Free Report) last announced its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $8.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.88 by $0.06. Humana had a return on equity of 20.70% and a net margin of 3.42%. The firm had revenue of $26.75 billion for the quarter, compared to analysts’ expectations of $25.83 billion. During the same quarter in the prior year, the firm posted $8.67 earnings per share. Humana’s revenue for the quarter was up 13.0% compared to the same quarter last year. On average, analysts anticipate that Humana Inc. will post 28.26 earnings per share for the current fiscal year.
Humana Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 29th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 0.72%. The ex-dividend date is Thursday, September 28th. Humana’s dividend payout ratio (DPR) is presently 13.21%.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Stories
- Five stocks we like better than Humana
- Stock Average Calculator
- How You Can Reverse Engineer Michael Burry’s Latest Buy
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- The Odds Are High Costco Will Declare a Special Dividend SoonÂ
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 Mid-Cap Momentum Plays to Ride Into Q4
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
